Michael Kamarck

Michael E.
Kamarck served as an Independent Director at Trillium Therapeutics ULC from 2020 to 2021.
He also held the position of Non-Executive Director at Unilife Corp.
in 2016 and 2017.
Additionally, he was an Independent Director at Omni Bio Pharmaceutical, Inc. from 2013 to 2015.
Dr. Kamarck currently holds the position of Independent Director at Vaxcyte, Inc. since 2021 and at Passage Bio, Inc. since 2022.
He previously served as the SVP-Global Vaccines & Biologics Manufacturing at Merck & Co., Inc. from 2009 to 2012.
He was also the Head-Therapeutic Monoclonal Antibodies at Sanofi in 2014.
Furthermore, he was the President of Merck BioVentures from 2009 to 2012 and the President of Technical Operations & Product Supply at Wyeth Pharmaceuticals, Inc. from 2001 to 2009.
Dr. Kamarck worked as a Principal at Willow Creek Biotech Consulting LLC from 2013 to 2017 and was a Member at TransForm Pharmaceuticals, Inc. He obtained his undergraduate degree from Oberlin College and holds a doctorate degree from the Massachusetts Institute of Technology.